{"entity":{"id":"nct04084496","kind":"trial","name":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","aka":[],"tldr":"A phase 2 trial of fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Sun Yat-sen University, now recruiting.","summary":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients is a phase 2, interventional study registered as NCT04084496 by Sun Yat-sen University, with a registry enrolment figure of 80 participants, started 2019-09-01 and due to reach its primary completion in 2024-12-31. Interventions recorded: Folfirinox. Conditions listed: Pancreatic Cancer. Primary outcome: Disease free survival. Pancreatic eligibility wording from the registry: \"* Histologically confirmed adenocarcinoma of the pancreas without distant metastases\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04084496","url":"https://clinicaltrials.gov/study/NCT04084496"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["folfirinox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04084496","phase":"2","setting":"A Phase II Study With mFOLFIRINOX as Adjuvent Chemotherapy for Resectable Pancreas Carcinoma","sponsor":"Sun Yat-sen University","participation":[{"nct":"NCT04084496","source":"https://clinicaltrials.gov/study/NCT04084496","fetchedAt":"2026-10-07T16:53:14.124Z","studySha256":"83f2bd25fe4601b0ee13b358b7d533ecc703e794d05fa9d9ef9dd5589ee69214","overallStatus":"RECRUITING","lastUpdatePosted":"2025-05-30","leadSponsor":"Sun Yat-sen University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"79 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":80,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2019-09-01","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04084496/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}